INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS -- INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS -- Contents -- Preface -- The Risk of Infection in Patients Treated with Infliximab -- Abstract -- 1. Definition and Functions of Tumour Necrosis Factor -- 2. Anti-TNF Mechanism of Action: Infliximab -- 3. Risk of Infections in the Use of Infliximab: Evidence -- 4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved -- 5. Other Risk Factors for Infection in Patients Treated with Infliximab -- 6. Infections -- Bacterial Infections -- Listeria -- Tuberculosis -- Virus -- Fungal Infections -- Histoplasmosis -- Coccidioidomycosis -- Cryptococcosis -- Aspergillosis -- Candidiasis -- Pneumocystosis -- 7. Special Situations -- Perisurgical Infections -- Hepatitis B Virus Infection -- Hepatitis C Virus Infection -- HIV Infection -- Vaccines -- Conclusions -- References -- Infliximab in Inflammatory Bowel Disease -- Abstract -- Pharmacology -- Uses -- Inflammatory Crohn's Disease -- Fistulizing Crohn's Disease -- Ulcerative Colitis -- Mucosal Healing -- Pouchitis -- Extraintestinal Manifestations -- Limitations -- Predictors of Response to Infliximab -- Infections -- Malignancies and Lymphoma -- Cutaneous, Neurological and Liver Manifestations -- Congestive Heart Failure -- Pregnancy -- References -- Infliximab: Up-to-Date on Indications and Warnings -- Abstract -- 1. Introduction -- 2. Pharmacology -- 2.1. Structure and Mechanisms of Action -- 2.2. Absorption -- 2.3. Distribution -- 2.4. Metabolism and Excretion -- 2.5. Dosage and Administration -- 2.6. Pharmacogenomics -- 2.7. Drug Interactions -- 3. Clinical Uses -- 3.1. Autoimmune Conditions -- a) Psoriatic Arthritis -- b) Rheumatoid Arthritis -- c) Ulcerative colitis (UC) -- d) Crohn's Disease (CD) -- e) Ankylosing Spondylitis -- f) Sarcoidosis -- g) Behçet Disease.

h) Polychondritis -- i) Giant Cell Arteritis -- j) Sjögren Syndrome -- k) Juvenile Idiopathic Arthritis (JIA) -- l) Eosinophilic Fasciitis -- 3.2. Dermatological Conditions -- A) Toxic Epidermic Necrolysis -- B) Subcorneal Pustular Dermatosis -- C) Pyoderma Gangrenosum -- D) Chronic Eczema -- E) Hidradenitis Susppurativa (HS) -- 3.3. Other Verified Uses -- a) SAPHO Syndrome -- b) Kawasaki Disease -- c) Pulmonary Fibrosis -- d) Cap Polyposis -- e) Postresuscitation Myocardial Dysfunction -- f) B-Chronic Lymphocytic Leukemia -- g) Diabetic Macular Edema -- 4. Warnings and Limitations -- 4.1. Serious Infections -- 4.2. Malignancies -- 4.3. Hepatitis B virus Reactivation -- 4.4. Hepatotoxicity -- 4.5. Patients with Heart Failure -- 4.6. Hematological and Vascular Events -- 4.7. Hypersensitivity -- 4.8. Neurological Events -- 4.9. Autoimmunity -- 4.10. Adverse Reactions in Pediatric Patients -- 4.11. Use in Pregnancy -- Conclusion -- References -- Infliximab in Inflammatory Bowel Diseases: Pharmacology, Uses and Limitations -- Abstract -- Introduction -- Pharmacology and Mechanism of Action -- Clinical Use in IBD -- Adverse Events and Limitations -- Conclusions -- References -- Efficacy and Safety of Infliximab during Pregnancy and Breastfeeding in Women with Inflammatory Bowel Disease -- Abstract -- Introduction -- Infliximab: Mecanism of Action -- Efficacy of Infliximab as a Treatment of IBD -- A. Efficacy as Induction Therapy for Inflammatory CD -- B. Maintenance after Induction of Remission with Anti-TNF Therapy -- C. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease -- D. Induction and Maintenance Therapy during Ulcerative Colitis -- Safety of Infliximab during Pregnancy -- Safety of Infliximab during Bearst Feeding -- Conclusion -- References -- Anti TNF's for Postoperative Recurrence of Crohn's Disease: The State of the Art.

Abstract -- Introduction -- Background -- History of CD Recurrence Post Surgical Resection -- Factors Affecting the Risk of Post Operative Recurrence -- Medications to Prevent Post Operative Recurrence -- Conventional Therapies -- Biologics -- What to Do Next? Clues from a Follow up Study -- Prevention vs Treatment and Other Open Questions -- Conclusions -- References -- Continuation Rate with Infliximab Therapy for Rheumatoid Arthritis Patients does not Necessarily Reflect Efficacy of Therapy in Real-World Practice -- Abstract -- Introduction -- Methods -- Literature Search -- Study Selection -- Patients and Assessment -- Analysis with Survival Rate and Clinical Response in Our Study -- Statistical Analysis -- Results -- Baseline Demographic and Clinical Characteristics -- Continuation of IFX Therapy -- Efficacy of IFX Therapy -- Continuation and Efficacy of IFX Therapy in Our Study -- Discussion -- Conclusions -- References -- Mechanism of Disease Amelioration on Infliximab Treatment: Novel Effecter Molecules for Pathogenesis of Rheumatoid Arthritis -- Abstract -- Introduction -- Connective Tissue Growth Factor (CTGF) -- Regenerating Gene 1α (REG 1α) -- Conclusion -- Acknowledgments -- References -- Index.